North America Drug Discovery Market – Size, Outlook, Trends and Forecast (2024 – 2032)

Drug discovery is a process of inventing a new medication in the field of pharmaceuticals, biotechnology, and pharmacology. It is a complex, lengthy and expensive process. Though advanced technologies are available, the success rate of drug discovery is very low and the time involved is relatively high.

North America Drug Discovery Market Segments Size & Growth:

North America drug discovery market size is projected to reach approximately $XX billion by the end of 2024 with a CAGR of close to XX% from $XX billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Rise in healthcare expenditure, Highly robust and populated pipeline for novel drugs and Improvement in the therapeutic discovery ventures. However, the Market shift from branded to generic drugs and Stringent regulations for drug discovery are thereby hampering the market growth.

North America Drug Discovery Market Segments Share:

North America drug discovery market is categorised into technology which comprises of QPCR, DNA microarrays, Protein microarrays, High-throughput screening, Mass spectrometry, Gel Electrophoresis, Chromatography, Protein and Nucleic acid isolation, and Others. By service, the market is segmented into Pharmaceutical Services, Drug Metabolism and Pharmacokinetics (DMPK) Services, Pharmaceutical Services, Chemical Services, and Biological Services. By End-users, the market is segmented into Biotech companies, Pharmaceutical companies, Biopharmaceuticals, Research Institutes, and Others. By Geography, USA is projected to dominate the market with the largest share and the growth in the North America economies is mainly attributed because of huge profit margins and growth prospects.

North America Drug Discovery Market Trends:

• Roche announced that it has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark.
• Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application to expand the indication for BOSULIF (bosutinib) to include adult patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).

North America Drug Discovery Market Research Report:

An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.

To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.

Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year

Identifying DROC in the current market and their impact in altering the market dynamics.

Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.

Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.

The primary market players, such as

• Johnson and Johnson
• AstraZeneca PLC
• Roche Holding AG
• Eli Lily
• Boehringer Ingelheim, INC.